Phibro Animal Health (NASDAQ:PAHC) Raised to “Strong-Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other equities research analysts have also commented on PAHC. Morgan Stanley boosted their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. JPMorgan Chase & Co. began coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Finally, Barclays increased their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.50.

Phibro Animal Health Stock Down 1.0 %

Phibro Animal Health stock opened at $20.52 on Friday. The stock’s 50 day moving average price is $23.01 and its 200 day moving average price is $20.99. Phibro Animal Health has a 1-year low of $10.03 and a 1-year high of $25.98. The company has a market cap of $831.12 million, a PE ratio of 47.72, a price-to-earnings-growth ratio of 0.58 and a beta of 0.53. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds have recently added to or reduced their stakes in PAHC. Sofinnova Investments Inc. purchased a new position in shares of Phibro Animal Health during the 2nd quarter worth approximately $3,975,000. American Century Companies Inc. grew its holdings in Phibro Animal Health by 119.6% during the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after buying an additional 189,068 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Phibro Animal Health by 116.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock worth $4,330,000 after buying an additional 103,491 shares in the last quarter. Dana Investment Advisors Inc. raised its holdings in shares of Phibro Animal Health by 17.2% in the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock worth $8,619,000 after acquiring an additional 75,546 shares during the last quarter. Finally, Algert Global LLC lifted its position in shares of Phibro Animal Health by 521.1% in the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock valued at $1,606,000 after acquiring an additional 59,850 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.